Search Results for “research” – Page 4 – media

LucyTx announces additional $12.5m research funding for neurological diseases

Lucy Therapeutics (LucyTx) has announced it has raised $12.5m in additional funding to develop potentially new drugs and advance the company’s research programmes for neurological diseases. The funding, provided by existing investors, Engine Ventures and Safar Partners, with recent participation from the Bill & Melinda Gates Foundation, the Michael J. Fox Foundation and £1.6m from Parkinson’s UK’s Biotech programme, brings the company’s total funding to $36m. The new project aims to develop novel therapies that are based on mitochondrial small-molecule treatments and diagnostic biomarkers for Alzheimer’s (AD) and Parkinson’s disease (PD), as well as continue the development of a novel drug target for Rett syndrome, a rare genetic neurological and developmental disorder that affects brain development. AD and PD are the two most common neurodegenerative diseases worldwide, affecting around 24 million and ten million people, respectively. Using LucyTx’s platform, the team will analyse a variety of disease drivers central to ...
- Source: drugdu
- 75
- June 14, 2024
US researchers develop AI liquid biopsy test to help identify lung cancer earlier

Researchers from the Johns Hopkins Kimmel Cancer Center and other institutions have developed and validated a liquid biopsy test using artificial intelligence (AI) to help identify lung cancer earlier. The new study published in Cancer Discovery demonstrated that the new blood test could help accelerate lung cancer screening while reducing death rates. Currently the leading cause of global cancer incidence and death worldwide, lung cancer accounts for an estimated two million diagnoses and 1.8 million deaths annually. For the last five years, researchers have developed a test to detect patterns of DNA fragments found in patients with lung cancer. Participants with and without cancer who met the criteria for low-dose computed tomography (CT) were recruited to receive the blood test to determine which patients were most at risk and would benefit from a follow-up CT screening to help overcome issues regarding appointments, such as the time it takes to arrange ...
- Source: drugdu
- 104
- June 14, 2024
Dana-Farber Cancer Institute and OncoHost partner for renal cell carcinoma research

The Dana-Farber Cancer Institute and OncoHost have partnered to research and identify biomarkers for renal cell carcinoma (RCC), a form of kidney cancer. The collaboration aims to create a proteomic plasma profile by providing OncoHost with materials using Dana-Farber’s repository of patient plasma samples and clinical data. According to Cancer Research UK, kidney cancer is the sixth most common cancer in the UK, accounting for 4% of all new cancer cases. RCC occurs when malignant cells are found in the lining of tubules in the kidney and there is currently no blood test available for these patients to help make personalised treatment recommendations, explained Wenxin Xu, physician, Dana-Farber and assistant professor of medicine at Harvard Medical School. For most RCC patients, immune-checkpoint inhibitor therapy (ICI) has been used to treat the disease. However, ICIs may not benefit all patients and can cause immune-related adverse events (irAEs). The PROPHETIC trial will ...
- Source: drugdu
- 153
- June 13, 2024
2024 ASCO | Benmelstobart monotherapy research results in gynecologic oncology and other areas updated

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4, local time. Chiatai Tianqing’s recently launched Class 1 innovative biologic Benmelstobart announced a number of research results at the meeting, covering the fields of digestive and gynecological oncology. Benmelstobart monoclonal antibody is an innovative humanized anti-PD-L1 monoclonal antibody with a new sequence, which was just approved for marketing in May 2024. The first approved indication is for the first-line treatment of patients with extensive-stage small-cell lung cancer (ES-SLC) in combination with amilotinib hydrochloride capsule, carboplatin and etoposide. Endometrial cancer is one of the most common gynecologic malignancies and its incidence is on the rise worldwide. Most patients with endometrial cancer are diagnosed at an early stage and have a good overall prognosis, with a 5-year survival rate of 95%. Once localized spread or distant metastasis occurs, the 5-year survival rate ...
- Source: drugdu
- 117
- June 13, 2024
International KCL research project to develop SMARTdrugs for aggressive cancers

The platform will be used to diagnose and treat cancers, including lung and brain tumours A new international study led by King’s College London (KCL) researchers is developing a radiotheranostic platform called SMARTdrugs for the diagnosis and treatment of aggressive forms of cancer. With partners in Munich, Zurich, San Sebastian and Utrecht, the study has been awarded a Pathfinder Open Grant of nearly €4m from the European Innovation Council. Aggressive cancers such as lung and brain tumours occur when the growth rate is impacted by the genetic makeup of the tumour and the rate at which the cells are dividing. Researchers aim to create supramolecular compounds as an alternative to the current standard of attaching radionuclides directly to drug molecules to allow clinicians to visualise key signatures of tumours using medical imaging systems. The supramolecular compounds will have greater control over their size, shape and other biochemical properties than other ...
- Source: drugdu
- 68
- June 5, 2024
The Crick announces new partnerships with SMEs and MRC for research

The projects will focus on a range of research areas, including Down’s syndrome and ALS The Francis Crick Institute has announced six new partnerships with small and medium-sized enterprises (SMEs) with support from the Medical Research Council (MRC) focused on innovative discovery projects led by Crick researchers. Supported by an MRC Business Engagement Fund Award, as part of UK Research and Innovation, the collaborations will focus on the application of novel cutting-edge technologies, encompassing a diverse range of research to deliver impactful outcomes. Paul Mercer, head of collaboration, the Crick, commented: “We are… excited to be able to develop these research partnerships with SMEs, diversifying the opportunity for development of Crick discoveries through the application of disruptive innovations.” Partners include Perha Pharmaceuticals, Scalable Minds, Broken String Biosciences, Hertility Health, Automata Technologies and Mytos. The projects will focus on a range of research, including pharmacological treatments for congenital heart defects in ...
- Source: drugdu
- 86
- June 4, 2024
Researchers identify genetic changes responsible for rare childhood immune disorders

Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns A new study led by Newcastle University has identified the genetic changes that are responsible for rare childhood immune disorders that can leave newborns with little to no immune defence against infections. Published in Science Immunology, the study involved experts from the Great North Children’s Hospital, the Wellcome Sanger Institute and their collaborators. Severe combined immunodeficiency (SCID) and Omenn syndrome are two rare genetic disorders that affect the function of children’s immune systems and put them at risk of life-threatening conditions. While the prevalence of Omenn syndrome is unknown, the various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns. Without urgent treatment, including stem cell transplants to replace the faulty immune system, most children affected will not survive their first year of life. Researchers studied 11 children, ...
- Source: drugdu
- 90
- June 3, 2024
NIHR awards HealthTech Research Centre Network £5m to advance health innovations

The network will support the development, evaluation and adoption of innovative health and care technology The National Institute for Health and Care Research (NIHR) has awarded an NIHR HealthTech Research Centre (HRC) Network £5m to provide national coordination and leadership for NIHR HRCs to advance health innovations. Hosted by Sheffield Teaching Hospitals NHS Foundation Trust from 1 September 2024, the network will support the development, evaluation and adoption of innovative health and care technology. In November 2023, the NIHR announced £42m in funding to support 14 new NIHR HRCs to work with businesses to support the development of medical devices, diagnostics and digital technologies to allow people to better monitor their health, make earlier diagnoses and improve the management of conditions such as cancer, dementia, cardiovascular and respiratory disease. The HRCs are located in leading NHS organisations across England, including Guy’s and St Thomas’ and King’s College London’s HRC for ...
- Source: drugdu
- 69
- May 23, 2024
Liverpool and McMaster University announce £300,000 strategic research partnership

Areas include health research across life stages, from paediatrics to health ageing and resilience The University of Liverpool and McMaster University have announced an institutional strategic partnership, offering £300,000 in seed funding to nine selected projects to support the development of collaborations in key areas of research. The areas of research include health research across life stages, from paediatrics to healthy ageing and resilience, along with social sciences, humanities and research, as well as development in port-related activities. The projects selected were announced by McMaster at a celebratory event with representatives from the University of Liverpool in attendance. The three health research projects selected focus on innovative antibiotic discovery to combat invasive Salmonella in Africa, engineering perfusable vascular organoids for ageing and chronic disease studies and developing pharmacogenetic polygenic risk scores using machine learning methods. David Farrar, president, McMaster, commented: “We’re proud to partner with the University of Liverpool to ...
- Source: drugdu
- 77
- May 21, 2024
NIHR and TJBCM announce new funding initiative for novel brain tumour research

The condition is the ninth most common cancer in the UK and affects 12,300 people annually The National Institute for Health and Care Research (NIHR) and the Tessa Jowell Brain Cancer Mission (TJBCM) have announced a new innovative package of research funding to stimulate brain tumour research in adults, children and young people. The announcement emerges from a collaboration between charities, research funders and the government, which pledged £40m to develop new lifesaving and life-improving research. Currently the ninth most common cancer in the UK, affecting around 12,300 people every year, according to the Brain Tumour Charity, brain tumours occur when a growth of cells in the brain multiplies in an abnormal, uncontrollable way. In 2018, members of the brain tumour community united to design a national strategy and the government committed funding for new research, following the late Dame Tessa Jowell’s call to action on behalf of brain tumour ...
- Source: drugdu
- 91
- May 17, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.